Phase 1 Glioblastoma, IDH-wildtype Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center24 enrolled1 locationNCT07544992
Recruiting
Phase 1
A Study of 177Lu-PSMA-617 in People With Gliomas
GliomaGlioblastoma, IDH-wildtypeDiffuse Midline Glioma, H3 K27-Altered+3 more
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07223034
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 1
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 1
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394
Recruiting
Phase 1Phase 2
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 1Phase 2
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Recurrent Glioblastoma, IDH-Wildtype
Tasly Pharmaceutical Group Co., Ltd26 enrolled1 locationNCT07318818
Recruiting
Phase 1
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
Recurrent Glioblastoma, IDH-Wildtype
Darell Bigner46 enrolled1 locationNCT06455605
Recruiting
Phase 1
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
GlioblastomaGBMGlioblastoma Multiforme+4 more
Orbus Therapeutics, Inc.66 enrolled8 locationsNCT05879367
Recruiting
Phase 1
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
GlioblastomaRadiotherapy; ComplicationsGlioblastoma Multiforme+2 more
Hospital San Carlos, Madrid12 enrolled1 locationNCT06418113